Bio-Techne Shareholders Approve Merck KGaA Acquisition Plan

Bio-Techne shareholders approved Merck KGaA's acquisition of the company, clearing a key milestone toward completion of the transaction. The approval materially reduces execution risk for the biotech deal, though the article did not disclose transaction value, timing, or remaining closing conditions.